Staff Members - Benha University
Effects of angiotensin receptor-neprilysin inhibitor on exercise capacity in patients with heart failure with reduced ejection fraction
• 2019
Publication Information
Authors
Mohamed Abdel Shafy Tabl, Tarek Samy Essawy
Keywords
heart failure; sacubitril/valsartan; cardiopulmonary exercise test.
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) is well known to be superior over angiotensin-
converting enzyme inhibitor (ACEI) or angiotensin receptor blockers (ARBs) in terms of reducing cardiovascular
mortality in heart failure with reduced ejection fraction (HFrEF). However the impact of sacubitril/
valsartan therapy on exercise capacity versus ACEI/ARBs for such patients is less tested.
Methods. This non randomized observational study enrolled 100 patients with HFrEF. All participants underwent
two sets of cardiopulmonary exercise tests (CPET) at baseline and after 6 months of non interrupted sacubitril/
valsartan therapy in addition to optimal anti failure medications. Bridging from ACEI/ARBs to ARNI was done at
baseline according to guidelines.
Results. After 6 months, patients received sacubitril/valsartan had significant improvement in LVEF from 26 ± 5 to
29.6 ± 8%, peak oxygen consumption (VO2) improved from 14.6 ± 4 to 17.3 ± 5.2 mL/kg/min, oxygen pulse increased
from 11.6 ± 4 to 13.6 ± 5 mL/kg/min and ΔVO2/ΔWork increased from 9.1 ± 2.5 to 10.2 ± 1.6 mL/min/watt (p =
0.0001 for all). Conclusion: Sacubitril/valsartan therapy improved exercise tolerance, peak oxygen consumption
and LVEF up to 6 months of follow-up.
converting enzyme inhibitor (ACEI) or angiotensin receptor blockers (ARBs) in terms of reducing cardiovascular
mortality in heart failure with reduced ejection fraction (HFrEF). However the impact of sacubitril/
valsartan therapy on exercise capacity versus ACEI/ARBs for such patients is less tested.
Methods. This non randomized observational study enrolled 100 patients with HFrEF. All participants underwent
two sets of cardiopulmonary exercise tests (CPET) at baseline and after 6 months of non interrupted sacubitril/
valsartan therapy in addition to optimal anti failure medications. Bridging from ACEI/ARBs to ARNI was done at
baseline according to guidelines.
Results. After 6 months, patients received sacubitril/valsartan had significant improvement in LVEF from 26 ± 5 to
29.6 ± 8%, peak oxygen consumption (VO2) improved from 14.6 ± 4 to 17.3 ± 5.2 mL/kg/min, oxygen pulse increased
from 11.6 ± 4 to 13.6 ± 5 mL/kg/min and ΔVO2/ΔWork increased from 9.1 ± 2.5 to 10.2 ± 1.6 mL/min/watt (p =
0.0001 for all). Conclusion: Sacubitril/valsartan therapy improved exercise tolerance, peak oxygen consumption
and LVEF up to 6 months of follow-up.